Moderna, Inc. (BVMF:M1RN34)

Market Cap	83.64B -13.4%
Revenue (ttm)	11.90B -56.1%
Net Income	-16.61B
EPS	-42.91
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,835
Average Volume	97,122
Open	10.99
Previous Close	10.88
Day's Range	10.33 - 10.99
52-Week Range	6.02 - 14.56
Beta	1.34
RSI	50.44
Earnings Date	Feb 13, 2026

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 5,800
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: M1RN34

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD